dBET1, CAS 1799711-21-9

Formulation: A crystalline solid

Formal Name: (6S)-4-(4-chlorophenyl)-N-[4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]butyl]-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide

Purity: ≥98%

Formula Markup: C38H37ClN8O7S

Formula Weight: 785,3

Shelf life (days): 1460

CAS Number: 1799711-21-9

Notes: dBET1 is a hybrid molecule that combines (+)-JQ1 (Item No. 11187) and thalidomide (Item No. 14610).{29054} The JQ1 portion facilitates binding of dBET1 to the bromodomains of BET family transcriptional activators. The thalidomide moiety drives proteasomal degradation, as phthalimides bind cereblon to create a substrate recognition site for E3 protein ligase complex-mediated ubiquitination. dBET1 induces cereblon-dependent BET protein degradation in vitro (EC50 = 430 nM) and in vivo and delays leukemia progression in mice.

• Artikelnummer: CAY18044-1
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 18044-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK